F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients

Benzinga2021-08-12

F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.
The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).
FS118 is a bispecific antibody targeting LAG-3 and PD-L1.
In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.
F-Star ended the quarter with cash and cash equivalents of $81.6 million.
Price Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

BowenDu
2021-08-13
BowenDu
Like and comment pls
1nu
2021-08-13
1nu
help me like and comment :)
- FunnyFun:
  Ok
- Singman:
  pls like too
卧升龙
2021-08-13
卧升龙
Ok
- JANICELSJ:
  Ok
Syww
2021-08-13
Syww
[Strong] [Strong]
Sonson89
2021-08-13
Sonson89
K
987ce65
2021-08-13
987ce65
Ok

发表看法

330

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2158268958?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-12 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2158268958","market":"us","top_or_hot":-1,"title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","media":"Benzinga","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-12 23:12 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FSTX","symbol_name":"F-star Therapeutics, Inc. ","start_time":0,"source_url":null,"article_id":"2158268958","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","pubTimestamp":1628781141,"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"\n","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"translate_title":"F-STAR的FS118开发计划将检查点幼稚癌症患者包括在内","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FSTX":0.9},"content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":894375487,"gmtCreate":1628809618149,"gmtModify":1633689400421,"author":{"id":"3574901428369611","authorId":"3574901428369611","authorIdStr":"3574901428369611","name":"BowenDu","avatar":"https://static.tigerbbs.com/b2b540981c00cc0005e6241f782bd3c5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574901428369611"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894375487","repostId":2158268958,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894344901,"gmtCreate":1628809021803,"gmtModify":1633689409691,"author":{"id":"3577610430427001","authorId":"3577610430427001","authorIdStr":"3577610430427001","name":"1nu","avatar":"https://static.tigerbbs.com/15789a74f3eb14371af59c44a8f71041","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577610430427001"},"htmlText":"help me like and comment :)","listText":"help me like and comment :)","text":"help me like and comment :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/894344901","repostId":2158268958,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5510239,"gmtCreate":1628809392733,"gmtModify":1635153005923,"authorId":3581664026895626,"author":{"id":3581664026895626,"authorId":3581664026895626,"name":"FunnyFun","avatar":"https://static.tigerbbs.com/e07aca58746125ec6ef6115042d363e9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894344901,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5510254,"gmtCreate":1628809470751,"gmtModify":1635153004428,"authorId":3575125836760247,"author":{"id":3575125836760247,"authorId":3575125836760247,"name":"Singman","avatar":"https://static.tigerbbs.com/d770feb757705f2d631d2d5f381ae07b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894344901,"type":1,"supId":0,"prevId":0,"content":"pls like <u>too</u>","text":"pls like <u>too</u>","html":"pls like <u>too</u>"}],"langContent":"EN"},{"id":894349901,"gmtCreate":1628808521103,"gmtModify":1633689415526,"author":{"id":"3579730769631306","authorId":"3579730769631306","authorIdStr":"3579730769631306","name":"卧升龙","avatar":"https://static.tigerbbs.com/e01d8942aa5f0e60c802ba77bcd46430","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579730769631306"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894349901","repostId":2158268958,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5510683,"gmtCreate":1628811258294,"gmtModify":1635152965589,"authorId":3579777216498074,"author":{"id":3579777216498074,"authorId":3579777216498074,"name":"JANICELSJ","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894349901,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":894340494,"gmtCreate":1628808497618,"gmtModify":1633689415874,"author":{"id":"4087953623473280","authorId":"4087953623473280","authorIdStr":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087953623473280"},"htmlText":"[Strong]&nbsp;[Strong]&nbsp;","listText":"[Strong]&nbsp;[Strong]&nbsp;","text":"[Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894340494","repostId":2158268958,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894357765,"gmtCreate":1628808471257,"gmtModify":1633689416936,"author":{"id":"3577445690140943","authorId":"3577445690140943","authorIdStr":"3577445690140943","name":"Sonson89","avatar":"https://static.tigerbbs.com/bb78553b48c28648b70634c067b819ec","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577445690140943"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894357765","repostId":2158268958,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894357401,"gmtCreate":1628808469903,"gmtModify":1633689417058,"author":{"id":"3582709856792743","authorId":"3582709856792743","authorIdStr":"3582709856792743","name":"987ce65","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582709856792743"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894357401","repostId":2158268958,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":330,"commentSize":27,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2158268958"}